Although hematopoietic stem cell transplantation (allogeneic SCT (allo-SCT)) is the treatment of choice for many aggressive hematological malignancies, the role of allo-SCT in chronic lymphocytic leukemia (CLL) is still a matter of debate and can be considered one of the more important challenges for the next decade. In the era of novel drugs and humanized antibodies, the long-term outcome of patients has improved, and a critical reappraisal of autologous and allo-SCT in CLL treatment is warranted.

中文翻译：

---

未来十年的挑战：慢性淋巴细胞白血病的异基因干细胞移植

尽管造血干细胞移植（同种异体 SCT (allo-SCT)）是许多侵袭性血液系统恶性肿瘤的首选治疗方法，但同种异体 SCT 在慢性淋巴细胞白血病 (CLL) 中的作用仍存在争议，可被视为一种治疗方法。未来十年更重要的挑战。在新药和人源化抗体时代，患者的远期预后有所改善，有必要对 CLL 治疗中的自体和同种异体 SCT 进行严格的重新评估。